Utilizing braf/mek inhibitors to reduce morbidity in a pediatric patient with ameloblastoma
Originally at sciencedirect.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
A single pediatric ameloblastoma case treated with BRAF/MEK inhibitors shows reduced surgical morbidity, indicating that oral surgeons and pediatric specialists may need to coordinate with oncology teams earlier in treatment planning.
Key points
- Case published online 9 October 2026 in JOMS by Heo, Cohen, Vargas, and Green.
- Targeted BRAF/MEK inhibitors used to shrink tumor pre-operatively, reducing extent of resection and morbidity.
- Applies to oral & maxillofacial surgeons managing pediatric ameloblastoma; suggests new multidisciplinary pathway.
- Signals potential shift from purely surgical protocols to neoadjuvant medical therapy in select cases.
Who should care
Read the original on Journal of Oral & Maxillofacial Surgery (JOMS)
Full reporting and any paywall content live on sciencedirect.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Is fluoride still safe for kids? A dentist breaks down what the research actually shows
- ·Research
Inflammasome-related transcriptomic profiles in periodontitis
- ·Research
Clinical efficacy of platelet-rich fibrin therapy during oral surgical interventions
- ·Regulatory
Making Sense of Medicare’s Dental Benefit: Top Five Questions from Learners